-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-06-26 Jasdeep Sabharwal MD PhD, Chen Dun MHS, Fasika A. Woreta MD MPH
-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-05-27 Myung Soo Chang MD, Seung Won Lee MD PhD, Yong Joon Kim MD PhD
-
Re: Chang et al.: Incident noninfectious uveitis risk after immune checkpoint treatment (Ophthalmology. 2024 Mar 22:S0161-6420(24)00198-2. doi: 10.1016/j.ophtha.2024.03.017. Online ahead of print) Ophthalmology (IF 13.1) Pub Date : 2024-05-27 Alan Y. Hsu MD, Chun-Ju Lin MD, Huan-Sheng Chen MD, Yi-Yu Tsai MD PhD
-
Positive Transillumination of an Orbital Dermoid Cyst Ophthalmology (IF 13.1) Pub Date : 2024-05-13 Josefina Herrera MD, Fiona Bonar MB FRCPath, Krishna Tumuluri MBBS FRANZCO
-
Intravital Imaging of the Human Cornea Reveals the Differential Effects of Season on Innate and Adaptive Immune Cell Morphodynamics Ophthalmology (IF 13.1) Pub Date : 2024-05-03 Mengliang Wu PhD, Xinyuan Zhang MBioMedSci, Senuri Karunaratne OD, Ji-hyun Lee BOptom, Edwin R. Lampugnani PhD, Kevin J. Selva PhD, Amy W. Chung PhD, Scott N. Mueller PhD, Holly R. Chinnery PhD, Laura E. Downie PhD
Defining how the in vivo immune status of peripheral tissues is shaped by the external environment has remained a technical challenge. We recently developed Functional in vivo confocal microscopy (Fun-IVCM) for dynamic, longitudinal imaging of corneal immune cells in living humans. This study investigated the effect of seasonal-driven environmental factors on the morphodynamic features of human corneal
-
Intravitreal Topotecan for Vitreous Seeds in Retinoblastoma: A Long-term Review of 91 Eyes Ophthalmology (IF 13.1) Pub Date : 2024-05-03 Mrittika Sen MD, Raksha Rao MS, Kaustubh Mulay MD, Vijay Anand P. Reddy MD, Santosh G. Honavar MD FRCOphth
To study the long-term efficacy of intravitreal topotecan (IVT) for vitreous seeds in eyes with retinoblastoma and risk factors for their recurrence. Retrospective, non-comparative, interventional study. Ninety-one eyes of 90 patients with retinoblastoma treated between January 2013 and April 2019. Patients with recurrent or refractory vitreous seeds after completion of intravenous or intra-arterial
-
Eye Care in Federally Qualified Health Centers Ophthalmology (IF 13.1) Pub Date : 2024-04-30 Maria A. Woodward MD MS, Patrice M. Hicks PhD MPH, Kristen Harris-Nwanyanwu MD, Bobeck Modjtahedi MD, R.V. Paul Chan MD, Emily L. Vogt BA, Ming-Chen Lu MS, Paula Anne Newman-Casey MD MS, American Academy of Ophthalmology Taskforce on Ophthalmology and Community Health Centers, R.V. Paul Chan MD, Aiyin Chen MD, Jeffery Henderer MD, Bobeck Modjtahedi MD, Kelly Muir MD, Paula Anne Newman-Casey MD MS,
To assess changes in vision care availability at Federally Qualified Health Centers (FQHCs) between 2017 and 2021 and whether neighborhood-level demographic social risk factors (SRFs) associated with eye care services provided by FQHCs. Secondary data analysis of the Health Resources and Services Administration (HRSA) data and 2017–2021 American Community Survey (ACS). Federally Qualified Health Centers
-
Re: Thibault et al.: Drug-induced uveitis related to checkpoint inhibitors and MAP-kinase inhibitors (Ophthalmology. 2024;131:249–251) Ophthalmology (IF 13.1) Pub Date : 2024-04-27 Jasmine H. Francis MD FACS, Julia Canestraro OD, David H. Abramson MD FACS
-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-04-27 Thomas Thibault MD, Romane Freppel PharmD, Hervé Devilliers MD PhD, Aurélie Grandvuillemin PharmD
-
An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report Number 42 Ophthalmology (IF 13.1) Pub Date : 2024-04-23 Elvira Agrón MA, Amitha Domalpally MD PhD, Qingyu Chen PhD, Zhiyong Lu PhD, Emily Y. Chew MD, Tiarnan D.L. Keenan BM BCh PhD, AREDS and AREDS2 Research Groups
To update the Age-Related Eye Disease Study (AREDS) simplified severity scale for risk of late age-related macular degeneration (AMD), including incorporation of reticular pseudodrusen (RPD), and to perform external validation on the Age-Related Eye Disease Study 2 (AREDS2). Post hoc analysis of 2 clinical trial cohorts: AREDS and AREDS2. Participants with no late AMD in either eye at baseline in AREDS
-
Extensive Macular Atrophy with Pseudodrusen-like appearance: Progression Kinetics and Late-Stage Findings Ophthalmology (IF 13.1) Pub Date : 2024-04-06 Alessio Antropoli MD, Lorenzo Bianco MD, Christel Condroyer BSc, Aline Antonio BSc, Julien Navarro MSc, Dorothée Dagostinoz MSc, Amine Benadji MD, José-Alain Sahel MD, Christina Zeitz PhD, Isabelle Audo MD PhD
To describe the clinical outcome and late-stage findings of extensive macular atrophy with pseudodrusen-like appearance (EMAP). Retrospective cohort study. Seventy-eight patients (156 eyes) affected by EMAP. We collected data on best-corrected visual acuity, kinetic perimetry, OCT, short-wavelength autofluorescence, and near-infrared autofluorescence findings. Genetic testing for the and genes was
-
Visual Field Outcomes in the Primary Tube Versus Trabeculectomy Study Ophthalmology (IF 13.1) Pub Date : 2024-04-04 Swarup S. Swaminathan MD, Alessandro A. Jammal MD PhD, Felipe A. Medeiros MD PhD, Steven J. Gedde MD, Primary Tube Versus Trabeculectomy Study Group, Steven Gedde M.D., Michael Banitt M.D., Donald Budenz M.D. M.P.H., Ta Chang M.D., Richard Lee M.D. Ph.D., Paul Palmberg M.D. Ph.D., Richard Parrish II M.D., Swarup Swaminathan M.D., Luis Vazquez M.D. Ph.D., Sarah Wellik M.D., Mark Werner M.D., Jeffrey
To describe visual field outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study. Cohort analysis. A total of 155 eyes (155 subjects) randomly assigned to treatment with tube shunt surgery (n = 84) or trabeculectomy with mitomycin C (n = 71). The PTVT Study was a multicenter randomized clinical trial comparing the safety and efficacy of trabeculectomy and tube shunt surgery in eyes without
-
Triamcinolone Acetonide Subconjunctival Injection as Stand-alone Inflammation Prophylaxis after Phacoemulsification Cataract Surgery Ophthalmology (IF 13.1) Pub Date : 2024-04-04 Neal H. Shorstein MD, Shannon E. McCabe MD, Mubarika Alavi MS, Marilyn L. Kwan PhD, Naveen S. Chandra MD
To compare the effectiveness and safety of a single injection of subconjunctival triamcinolone acetonide (TA) with that of postoperative topical prednisolone acetate (PA) with and without nonsteroidal anti-inflammatory drugs (NSAIDs) for cataract surgery prophylaxis. Retrospective, comparative effectiveness cohort study. Patients at Kaiser Permanente Northern California from 2018 through 2021. Exposure
-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-04-03 Sean T. Berkowitz MD MBA, Avni P. Finn MD MBA, Ravi Parikh MD MPH, Ajay E. Kuriyan MD MS, Shriji Patel MD MBA
-
Re: Berkowitz et al.: Ophthalmology workforce projects in the United States, 2020 to 2035 (Ophthalmology. 2024;131:133–139) Ophthalmology (IF 13.1) Pub Date : 2024-04-03 Flora Lum MD, Ravi D. Goel MD
-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-04-01 Ingrid U. Scott MD MPH, Neal L. Oden PhD, Paul C. VanVeldhuisen PhD, Michael S. Ip MD, Barbara A. Blodi MD
-
Re: Scott et al.: SCORE2 Report 24: Nonlinear relationship of retinal thickness and visual acuity in central retinal and hemiretinal vein occlusion. (Ophthalmology. 2023;130:1066–1072) Ophthalmology (IF 13.1) Pub Date : 2024-04-01 Peng Wu MD, Rongyu Gao MD, Guangsen Liu MD
-
Post hoc Analysis of Role of Etanercept in Ocular Sequelae of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Ophthalmology (IF 13.1) Pub Date : 2024-03-30 Li-Yen Pan MD, Chuang-Wei Wang PhD, Tsung-Ying Tsai MD, Shin-Yi Chen MD, Kevin Sheng-Kai Ma DDS, Wen-Hung Chung MD PhD, Chun-Bing Chen MD PhD, Chi-Chin Sun MD PhD, Lung-Kun Yeh MD PhD, Hung-Chi Chen MD PhD, David Hui-Kang Ma MD PhD
-
Trends in Plasma Exchange Use in Optic Neuritis Hospitalizations in the United States Ophthalmology (IF 13.1) Pub Date : 2024-03-27 Sinan Akosman BA, Renxi Li BS, Masumi Asahi DO, Bryan Kwon BA, Jason Dossantos BS, Mehdi Tavakoli MD, John J. Chen MD PhD
To report use trends of plasma exchange (PLEX) as well as sociodemographic and medical comorbidities associated with PLEX in the United States. Retrospective cross-sectional study. Adult patients (≥ 18 years) admitted for inpatient hospitalization with a primary diagnosis of optic neuritis (ON). Data from the National Inpatient Sample database was compiled to assess PLEX use rates between 2000 and
-
Incident Noninfectious Uveitis Risk after Immune Checkpoint Inhibitor Treatment Ophthalmology (IF 13.1) Pub Date : 2024-03-22 Myung Soo Chang MD, Seung Won Lee MD PhD, Sunyeup Kim BSc, Christopher Seungkyu Lee MD PhD, Suk Ho Byeon MD PhD, Sung Soo Kim MD PhD, Yong Joon Kim MD PhD
-
Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report Ophthalmology (IF 13.1) Pub Date : 2024-03-16 Xiu Juan Zhang PhD, Yuzhou Zhang PhD, Benjamin H.K. Yip PhD, Ka Wai Kam FCOphthHK MSc, Fangyao Tang PhD, Xiangtian Ling MMed, Mandy P.H. Ng MHM, Alvin L. Young FRCSI MMedSc, Pei-Chang Wu MD, Clement C. Tham FCOphthHK FRCOphth, Li Jia Chen PhD FCOphthHK, Chi Pui Pang DPhil, Jason C. Yam MD FCOphthHK
To evaluate (1) the long-term efficacy of low-concentration atropine over 5 years, (2) the proportion of children requiring re-treatment and associated factors, and (3) the efficacy of pro re nata (PRN) re-treatment using 0.05% atropine from years 3 to 5. Randomized, double-masked extended trial. Children 4 to 12 years of age originally from the Low-Concentration Atropine for Myopia Progression (LAMP)
-
Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial Ophthalmology (IF 13.1) Pub Date : 2024-03-15 Michael X. Lin BA, Lee Guo OD, Ian J. Saldanha MBBS PhD, Shanna VanCourt MS, Julia Zeng BS, Sezen Karakus MD, Michelle Hessen OD, Gavin Li BS, Esen K. Akpek MD
To evaluate a commercially available dexamethasone intracanalicular insert to treat dry eye. Single-center, double-masked randomized controlled trial. Patients with clinically significant aqueous-deficient dry eye (combined ocular surface staining score, ≥ 3 [0–12]; corneal fluorescein staining score, ≥ 2 [0–6]; and Schirmer’s wetting, < 10 mm at 5 minutes in both eyes) with symptoms (dryness, eye
-
An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper Ophthalmology (IF 13.1) Pub Date : 2024-03-14 Jennifer S. Steger PhD, Indira Durai MD, Annamalai Odayappan MD, Ramalakshmi Raman MsC, Talla Sruthi MD, Allisa J. Song BS, George Puthuran MD, Rengaraj Venkatesh MD, Elizabeth Colantuoni PhD, Alan L. Robin MD
To examine if 12.5 μl timolol maleate 0.5% microdrops dispensed with the Nanodropper Adaptor provide noninferior intraocular pressure (IOP) reduction compared with conventional 28 μl drops in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). Prospective, noninferiority, parallel, multicenter, single-masked, active-controlled, randomized trial. Treatment-naïve subjects who were
-
Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes Ophthalmology (IF 13.1) Pub Date : 2024-03-13 Siar Niazi MD, Filip Gnesin MD, Anna-Sophie Thein MD, Jens R. Andreasen MSc Bioinformatics, Anna Horwitz MD PhD, Zaynab A. Mouhammad MD, Baker N. Jawad MD, Zia Niazi MD, Nelsan Pourhadi MD, Bochra Zareini MD PhD, Amani Meaidi MD PhD, Christian Torp-Pedersen PhD, Miriam Kolko PhD
To examine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development of glaucoma in individuals with type 2 diabetes. Nationwide, nested case-control study. From a nationwide cohort of 264 708 individuals, we identified 1737 incident glaucoma cases and matched them to 8685 glaucoma-free controls, all aged more than 21 years and treated with metformin and a second-line
-
Medial Canthal Collision Tumor with Seborrheic Keratosis Hiding Underlying Basal Cell Carcinoma Ophthalmology (IF 13.1) Pub Date : 2024-03-08 Wenyu Deng MD, Jodi Sassoon MD, Roman Shinder MD FACS
-
Ocular Mucous Membrane Pemphigoid: The Effect of Risk Factors at Presentation on Treatment Outcomes Ophthalmology (IF 13.1) Pub Date : 2024-03-06 Raul E. Ruiz-Lozano MD, Maria F. Colorado-Zavala MD, Eugenia M. Ramos-Dávila MD, Manuel E. Quiroga-Garza MD, Nadim S. Azar MD, Hazem M. Mousa MD, Julio C. Hernández-Camarena MD PhD, Sandra S. Stinnett DrPH, Melissa Daluvoy MD, Terry Kim MD, Maite Sainz-de-la-Maza MD, Russell P. Hall 3rd MD, Alejandro Rodriguez-Garcia MD, Victor L. Perez MD
Analyze the influence of risk factors at presentation in the long-term immunosuppressive therapy (IMT) outcomes of ocular mucous membrane pemphigoid (OMMP). Retrospective multicenter study. Patients with OMMP seen at the Duke Eye Center, Tecnologico de Monterrey, and Hospital Clinic of Barcelona from 1990 to 2022. Data at presentation on demographics, direct immunofluorescence, ocular findings, sites
-
Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study Ophthalmology (IF 13.1) Pub Date : 2024-02-28 Byron L. Lam MD, Mark E. Pennesi MD PhD, Christine N. Kay MD, Sushil Panda MD, James A. Gow MD, Guolin Zhao PhD, Robert E. MacLaren DPhil, XIRIUS Study Group, Robert MacLaren MD PhD, Tomas Aleman MD, David Birch PhD, Assad Jalil MD, Andrew Lotery MD, Byron Lam MD, Mark Pennesi MD PhD, Christine N. Kay MD, Imram H. Yusuf MD PhD, Jasmina Cehajic Kapetanovic MD, Jasleen K. Jolly MSc PhD, Amandeep S. Josan
Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) is an investigational vector-based gene therapy designed to provide a full-length, codon-optimized retinitis pigmentosa GTPase regulator (RPGR) protein to individuals with -associated X-linked retinitis pigmentosa (XLRP). We assessed efficacy and tolerability of cotoretigene toliparvovec subretinal gene therapy. Part 2 of the XIRIUS trial ( identifier,
-
Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension Ophthalmology (IF 13.1) Pub Date : 2024-02-27 Steven R. Sarkisian Jr. MD, Robert E. Ang MD, Andy M. Lee MD, John P. Berdahl MD, Sebastian B. Heersink MD, James H. Burden MD, Long V. Doan PhD MSPH, Kerry G. Stephens OD, Angela C. Kothe OD PhD, Dale W. Usner PhD, L. Jay Katz MD, Tomas Navratil PhD, GC-010 Travoprost Intraocular Implant Investigators, Robert E. Ang MD, Sebastian B. Heersink MD, Steven Vold MD, Neil Atodaria MD, Jacob Brubaker MD
To evaluate the safety and intraocular pressure (IOP)-lowering efficacy of 2 models of the travoprost intraocular implant (fast-eluting [FE] and slow-eluting [SE] types) from 1 of 2 phase 3 trials (the GC-010 trial). Multicenter, randomized, double-masked, sham-controlled, noninferiority trial. Patients with open-angle glaucoma or ocular hypertension having an unmedicated baseline mean diurnal IOP
-
The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations Ophthalmology (IF 13.1) Pub Date : 2024-02-24 Priya Shukla BS, Neha Sharma BA MPH, Jacqueline K. Shaia MS, Devon A. Cohen MD, Rishi P. Singh MD, Katherine E. Talcott MD
To determine the risk of optic neuritis (ON) after mRNA Coronavirus Disease 2019 (COVID-19) vaccine administration. U.S. National aggregate database retrospective cohort study. Patients were placed into cohorts based on mRNA COVID-19 vaccination status (no vaccine and positive history of COVID-19 infection, 1 vaccine, or 2 vaccines received) from December 2020 to June 2022. Two control cohorts were
-
-
-
-
-
-
-
-
Severe, Rebound Mpox in an Immunocompromised Man Ophthalmology (IF 13.1) Pub Date : 2024-02-19 Adam J. Neuhouser, Alisha Kamboj
-
Pleomorphic Adenoma Misdiagnosed as Chalazion Ophthalmology (IF 13.1) Pub Date : 2024-02-19 Ruimiao Li, Mingyu Ren, Limin Liu
-
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 Ophthalmology (IF 13.1) Pub Date : 2024-02-19 Arshad M. Khanani MD MA, Aachal Kotecha PhD, Andrew Chang MBBS PhD, Shih-Jen Chen MD, Youxin Chen MD, Robyn Guymer MBBS PhD, Jeffrey S. Heier MD, Frank G. Holz MD, Tomohiro Iida MD, Jane A. Ives MSc, Jennifer I. Lim MD, Hugh Lin MD MBA, Stephan Michels MD MBA, Carlos Quezada Ruiz MD FASRS, Ursula Schmidt-Erfurth MD, David Silverman MSc MBChB, Rishi Singh MD FASRS, Balakumar Swaminathan MSc, Jeffrey
To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. TENAYA ( identifier, ) and LUCERNE ( identifier, ) were identically designed, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials. Treatment-naive patients with neovascular age-related macular degeneration (nAMD) 50 years of age or
-
Optic Disc Melanocytoma: Apparent Shrinkage after Posterior Vitreous Detachment Ophthalmology (IF 13.1) Pub Date : 2024-02-16 Michael Balas, Mark Mandell, Parnian Arjmand
-
A Remote Consult Retinal Artery Occlusion Diagnostic Protocol Ophthalmology (IF 13.1) Pub Date : 2024-02-13 Gareth M.C. Lema MD PhD, Reade De Leacy MD, Michael G. Fara MD PhD, Robin N. Ginsburg MD, Alexander Barash MD, Bryana Banashefski BS, James C. Tsai MD MBA, Richard B. Rosen MD
To report a novel protocol for diagnosis of retinal artery occlusions at the point of care using OCT and a remote consult model. Retrospective case series and evaluation of a diagnostic test or technology. Adult patients who presented with painless monocular vision loss and were diagnosed with a nonarteritic retinal artery occlusion. OCT machines were placed in the stroke center or emergency department
-
Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study Ophthalmology (IF 13.1) Pub Date : 2024-02-13 Alessandro Rabiolo MD, Giovanni Montesano MD, David P. Crabb PhD, David F. Garway-Heath MD FRCOphth, United Kingdom Glaucoma Treatment Study Investigators, David F. Garway-Heath MD, David P. Crabb PhD, Catey Bunce DSc, Gerassimos Lascaratos MSc, Francesca Amalfitano BSc, Nitin Anand MD, Augusto Azuara-Blanco PhD, Rupert R. Bourne MD, David C. Broadway MD, Ian A. Cunliffe FRCOphth, Jeremy P. Diamond
To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatment). Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest
-
Blepharitis Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-13 Amy Lin MD, Sumayya Ahmad MD, Guillermo Amescua MD, Albert Y. Cheung MD, Daniel S. Choi MD, Vishal Jhanji MD FRCS FRCOphth, Shahzad I. Mian MD, Michelle K. Rhee MD, Elizabeth T. Viriya MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Bacterial Keratitis Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-13 Michelle K. Rhee MD, Sumayya Ahmad MD, Guillermo Amescua MD, Albert Y. Cheung MD, Daniel S. Choi MD, Vishal Jhanji MD FRCS FRCOphth, Amy Lin MD, Shahzad I. Mian MD, Elizabeth T. Viriya MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Reply Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Shreya A. Shah BS, Linus Amarikwa MD, Connie M. Sears MD, Kevin D. Clauss MD, Raneem D. Rajjoub MD, Julia Y. Kang MD MPH, Madhura A. Tamhankar MD, César A. Briceño MD, Andrew R. Harrison MD, Kimberly P. Cockerham MD, Sara T. Wester MD, Raymond S. Douglas MD PhD, Chrysoula Dosiou MD MS, Andrea L. Kossler MD
-
Dry Eye Syndrome Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Guillermo Amescua MD, Sumayya Ahmad MD, Albert Y. Cheung MD, Daniel S. Choi MD, Vishal Jhanji MD FRCS FRCOphth, Amy Lin MD, Shahzad I. Mian MD, Michelle K. Rhee MD, Elizabeth T. Viriya MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Adult Strabismus Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Linda R. Dagi MD, Federico G. Velez MD, Jonathan M. Holmes MD, Steven M. Archer MD, Mitchell B. Strominger MD, Stacy L. Pineles MD, Evelyn A. Paysse MD, Matthew Simon Pihlblad MD, Hatice Tuba Atalay MD, Brian N. Campolattaro MD, Yoon-Hee Chang MD PhD, American Academy of Ophthalmology Preferred Practice Pattern Adult Strabismus Panel
-
Corneal Edema and Opacification Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Shahzad I. Mian MD, Elizabeth T. Viriya MD, Sumayya Ahmad MD, Guillermo Amescua MD, Albert Y. Cheung MD, Daniel S. Choi MD, Vishal Jhanji MD FRCS FRCOphth, Amy Lin MD, Michelle K. Rhee MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Corneal Ectasia Preferred Practice Pattern® Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Vishal Jhanji MD FRCS FRCOphth, Sumayya Ahmad MD, Guillermo Amescua MD, Albert Y. Cheung MD, Daniel S. Choi MD, Amy Lin MD, Shahzad I. Mian MD, Michelle K. Rhee MD, Elizabeth T. Viriya MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Conjunctivitis Preferred Practice Pattern Ophthalmology (IF 13.1) Pub Date : 2024-02-12 Albert Y. Cheung MD, Daniel S. Choi MD, Sumayya Ahmad MD, Guillermo Amescua MD, Vishal Jhanji MD FRCS FRCOphth, Amy Lin MD, Shahzad I. Mian MD, Michelle K. Rhee MD, Elizabeth T. Viriya MD, Francis S. Mah MD, Divya M. Varu MD, American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel
-
Unilateral Lipemic Aqueous Ophthalmology (IF 13.1) Pub Date : 2024-02-11 Junran Sun, Yuanyuan Gong, Suqin Yu
-
Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2024;131:458-467) Ophthalmology (IF 13.1) Pub Date : 2024-02-10 Terry J. Smith MD
-
Image Artifact on Swept-Source Anterior-Segment OCT after Descemet Membrane Endothelial Keratoplasty Ophthalmology (IF 13.1) Pub Date : 2024-02-10 Promporn Patarajierapun, Edmund Tsui, Simon S.M. Fung
-
Re: Margolis et al.: Six myths of the anterior segment: misunderstandings and critical thinking in ophthalmology (Ophthalmology. 2023;130:783-785) Ophthalmology (IF 13.1) Pub Date : 2024-02-10 Uma D. Chaluvadi MD FRCOphth
-
Cataract Surgery and Cognitive Benefits in the Older Person: A Systematic Review and Meta-analysis Ophthalmology (IF 13.1) Pub Date : 2024-02-08 Brian Sheng Yep Yeo MBBS, Rebecca Yi Xuan Ong MBBS, Pooja Ganasekar MBBS, Benjamin Kye Jyn Tan MBBS(Hons), Dennis Chuen Chai Seow FRCP(Ed) FAMS(Geriatric Medicine), Andrew S.H. Tsai FRCOphth MCI
This systematic review and meta-analysis aims to clarify the association of cataract surgery with cognitive impairment and dementia. The association between vision impairment and cognitive decline is well-established. However, the cognitive benefits of cataract surgery are less clear. Given the lack of cure for dementia, identifying modifiable risk factors is key in caring for patients with cognitive
-
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40 Ophthalmology (IF 13.1) Pub Date : 2024-02-08 Chirag D. Jhaveri MD, Danni Liu MSPH, Maureen G. Maguire PhD, Adam R. Glassman MS, Ruben A. Grigorian MD, Lee M. Jampol MD, Ronald M. Kingsley MD, Mathew W. MacCumber MD, Daniel F. Martin MD, Raj K. Maturi MD, Gisela Velez MD MPH MA, Jennifer K. Sun MD MPH, DRCR Retina Network
To identify factors for meeting prespecified criteria for switching from bevacizumab to aflibercept in eyes with center-involved diabetic macular edema (CI-DME) and moderate vision loss initially treated with bevacizumab in DRCR Retina Network protocol AC. Post hoc analysis of data from a randomized clinical trial. Two hundred seventy participants with one or both eyes harboring CI-DME with visual
-
Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis Ophthalmology (IF 13.1) Pub Date : 2024-02-05 Euna B. Koo MD, Tiffany M. Yu, Andrew J. Layton, Steven Babineaux MS RPh, Simon Fung MD MA (Oxon)
In this claims analysis, vernal keratoconjunctivitis (VKC) patients (≤18 years) treated with immunomodulators or corticosteroids had more corneal complications and higher ophthalmic care costs versus matched non-VKC controls, indicating a need for more effective treatments.
-
Trends and Sociodemographic Patterns in Keratoconus Management 2015–2020: An American Academy of Ophthalmology IRIS® Registry Analysis Ophthalmology (IF 13.1) Pub Date : 2024-02-03 Zeba A. Syed MD, Maurizio Tomaiuolo PhD, Qiang Zhang PhD, Venkatesh Prajna MD, Leslie Hyman PhD, Christopher J. Rapuano MD, IRIS® Registry Analytic Center Consortium∗, Aaron Y. Lee MD MSCI, Cecilia S. Lee MD MS, Russ Van Gelder MD PhD, Alice Lorch MD MPH, Joan W. Miller MD, Suzann Pershing MD MS, Jeffrey Goldberg MD PhD
Investigate trends in keratoconus (KCN) treatment patterns and diagnosis age from 2015 to 2020 and evaluate sociodemographic associations with the treatment approach. Retrospective cohort study. Patients with a new KCN diagnosis from 2015 to 2020 were identified in the Academy IRIS® Registry (Intelligent Research in Sight). Associations between sociodemographic factors and treatment were evaluated
-
Association of Cutaneous Keloids, Hypertrophic Scarring, and Fibrosis with Risk of Postoperative Proliferative Vitreoretinopathy Ophthalmology (IF 13.1) Pub Date : 2024-02-01 Danny A. Mammo MD, Karen Wai MD, Ehsan Rahimy MD, Carolyn K. Pan MD, Sunil K. Srivastava MD, Prithvi Mruthyunjaya MD
To assess an association between cutaneous keloids, hypertrophic scarring, and fibrosis (KHF) and risk of postoperative proliferative vitreoretinopathy (PVR) after rhegmatogenous retinal detachment (RRD) repair. Retrospective, population-based cohort study. Patients aged ≥ 18 years who underwent initial retinal detachment (RD) repair with pars plana vitrectomy with or without scleral buckle (SB) (Current
-
Predictive Performance of an Updated Polygenic Risk Score for Age-Related Macular Degeneration Ophthalmology (IF 13.1) Pub Date : 2024-02-01 Chenglong Yu PhD, Liubov Robman MBBS PhD, Weixiong He PhD, Robyn L. Woods PhD, Le Thi Phuong Thao PhD, Rory Wolfe PhD, James Phung BBiomedSc, Galina A. Makeyeva MBBS PhD, Lauren A.B. Hodgson MPH, John J. McNeil MD PhD, Robyn H. Guymer MBBS PhD, Stuart MacGregor PhD, Paul Lacaze PhD
A recent genome-wide association study of age-related macular degeneration (AMD) identified new AMD-associated risk variants. These variants now can be incorporated into an updated polygenic risk score (PRS). This study aimed to assess the performance of an updated PRS, PRS2023, in an independent cohort of older individuals with retinal imaging data and to compare performance with an older PRS, PRS2016